Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.34 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3154778 | 0.82 | NPC1 (0.35) | SMN1; SMN2NPC1RAB9AKCNH2 | |
| SCHEMBL1221701 | 0.80 | RAB9A (0.59) | SMN1; SMN2NPC1RAB9AKCNH2ALDH1A1 | |
| SCHEMBL3154722 | 0.80 | LTA4H (0.37) | SMN1; SMN2NPC1RAB9AKCNH2ALDH1A1 | |
| SCHEMBL864159 | 0.79 | KDM4E (0.58) | SMN1; SMN2KCNH2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL3170500 | 0.79 | NPC1 (0.37) | SMN1; SMN2NPC1RAB9AKCNH2CYSLTR2 | |
| SCHEMBL11433084 | 0.78 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AKCNH2KDM4E | |
| SCHEMBL7252796 | 0.76 | KDM4E (0.41) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL30354883 | 0.75 | MAOB (0.57) | SMN1; SMN2NPC1RAB9AALDH1A1CYP3A4 | |
| SCHEMBL864959 | 0.74 | HDAC1 (0.37) | SMN1; SMN2RAB9AKDM4EALDH1A1MAOB | |
| SCHEMBL4053035 | 0.74 | FFAR1 (0.48) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621278-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2013-08-07 | — | — | EP | claimed |
| US-8476302-B2 | α-ketoamide derivatives useful endothelial lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-02 | — | — | US | claimed |
| WO-2012047580-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-12 | — | — | WO | claimed |
| US-20120077847-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-29 | — | — | US | claimed |
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | claimed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | claimed |
| EP-2621278-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2013-08-07 | — | — | EP | disclosed |
| US-8476302-B2 | α-ketoamide derivatives useful endothelial lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-02 | — | — | US | disclosed |
| WO-2012047580-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-12 | — | — | WO | disclosed |
| US-20120077847-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-29 | — | — | US | disclosed |
| EP-1630165-B1 | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | NIPPON KAYAKU KK (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1630165-A1 | [1,2,4 ]TRIAZOLO [1,5-A]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2006-03-01 | — | — | EP | disclosed |
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1138680-A1 | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | SMN1; SMN2 3178/4885NPC1 1668/4885RAB9A 1475/4885 |
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | SMN1; SMN2 2083/4885NPC1 2604/4885RAB9A 1591/4885 |
| US-20120077847-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | LIPG, LIPA, LIPE | SMN1; SMN2 4361/4885NPC1 591/4885RAB9A 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.